Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Jorge E. Romaguera, Michael Wang, Lei Feng, Luis E. Fayad, Frederick Hagemeister, Peter McLaughlin, M. Alma Rodriguez, Michelle Fanale, Robert Orlowski, Larry W. Kwak, Sattva Neelapu, Yasuhiro Oki, Barbara Pro, Anas Younes, Felipe Samaniego, Nathan Fowler, Kimberly Hartig, Marisa Valentinetti, Judy Smith, Peggy FordAdam Naig, L. Jeffrey Medeiros, Hagop M. Kantarjian, Andre Goy

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences